BLACK WEEKSViaalid −15% · komplektid −10% · muu −5%koodigaTasuta tarne Saksamaal alates €200

See leht on tõlgitud automaatselt ja võib sisaldada vigu. Kas eesti keel on sinu emakeel? Ootame hea meelega sinu tagasisidet ja parandusi.Saada tagasisidet

The Peptide Desk The Peptide Desk
Dapagliflozin (Forxiga), toote foto
Medication

Dapagliflozin (Forxiga)

Medication

  • Saadetakse Saksamaalt

Tellimus

Ühiku hind - Black Weeksi ajal tasuta tarne Saksamaal alates 200 €
  • DHL koos jälgimisega
  • Diskreetne pakend

4.6 5-st Trustpilotis73 arvustust

Lühidalt

Dapagliflozin (Forxiga) arvudes

Põhinäitajad meie leksikonist. Lohista punkti mööda kõverat, et näha, kui palju jääb pärast ühte annust arvutuslikult alles.

Täielik leksikoni artikkel

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~12.9 hours

Half-life ~12.9 hours
After 26 hours: 25 %
Hour 1350 %Hour 24, next dose28 %Hour 2625 %Hour 3912.3 %Hour 653 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Half-life

about12.9hours

Class
SGLT2 inhibitorgliflozin, selective
Use
Oral1x daily
Sizes
10 mg1 size in the shop

Dapagliflozin (Forxiga) jaoks pole veel laborianalüüsi. Hääleta selle pooltLase ise testida, meie maksame pooleKõik laborianalüüsid

Teadmised

Kõik teemal Dapagliflozin (Forxiga)

FAQ

Korduma kippuvad küsimused

Allikad iga vastuse juurde: leksikoni artikkel

Kas sul on veel küsimusi?

Kirjuta meile, meie meeskond aitab sind.

How does dapagliflozin work?

It blocks the transporter SGLT2 in the kidney, which brings filtered sugar back into the blood. The sugar then leaves with the urine without insulin being needed. Breakdown runs mainly via the enzyme UGT1A9 to an inactive metabolite.

Does it help without diabetes?

In the trials on heart failure and chronic kidney disease the effect was similar with and without diabetes. With reduced pumping the risk of worsening or cardiac death fell by 26 percent.

What did the kidney trial show?

Among 4,304 participants 9.2 percent on dapagliflozin and 14.5 percent on placebo had an event (halved kidney function, kidney failure or death). 19 had to be treated to prevent one. The trial was therefore stopped early.

What is euglycaemic ketoacidosis?

Acidosis from ketones with nearly normal blood sugar. Because sugar does not rise much, it was recognised late in a case series. The authors advise checking ketones in case of nausea, vomiting or malaise. In the large diabetes trial it occurred in 0.3 versus 0.1 percent.

Does it lower heart attacks and strokes?

Not clearly in the diabetes trial with 17,160 patients: 8.8 versus 9.4 percent major cardiovascular events. Hospital stays for heart failure and kidney events did fall clearly.

Which side effects are known?

Serious genital infections or those leading to a stop occurred in 0.9 versus 0.1 percent, ketoacidosis in 0.3 versus 0.1 percent. In the heart failure trials volume depletion, kidney problems and low blood sugar were not more common than on placebo.

Seotud

Seotud tooted